While their animal study has not yet been peer-reviewed, it did show that the mix of two antibodies was able to “almost completely block the establishment of virus infection.”
In a second study where they had animals with higher levels of the virus, their drug was also able to have lower infection rates.
The CNBC also reported that Eli Lilly has started to have the last stages and trials for its drug. They are looking forward to testing it in order to prevent the spread of COVID-19 in nursing homes. Eli Lilly is using mobile research labs to make the study possible.
Monoclonal antibodies are being used in both the Regeneron and Eli Lilly drug trials.
Mark Brunswick of Sorrento Therapeutics said this kind of treatment is “basically instant immunity” against a virus. The company is also looking forward to human trials on its single treatment by next month.
With the belief of many in antibodies, Florian Krammer, microbiology professor at Icahn School of Medicine, stressed that antibodies have a chance of working well if given early. But it may not still be the case if given later on.


You must be logged in to post a comment.